FRIDAY 15 SEPTEMBER

13:00 - 14:00

Abbvie

Defining treatment strategies and comorbidities in JIA: Is there evidence for clinical consistency to optimize clinical practice?

Chair: Angelo Ravelli (Italy)

Banquet Hall


13:00

Welcome and introduction

Angelo Ravelli (Italy)

13:05

New paradigms in treat-to-target for JIA

Angelo Ravelli (Italy)

13:20

Seeking clinical consistency in the treatment of pediatric uveitis: What do the data tell us?

Athimalaipet V. Ramanan (United Kingdom)

13:35

Translating the data into real-world clinical practice

Eric Fortin (Canada)

13:50

Panel discussion

All

   

13:00 - 14:00

Pfizer

Treatment strategies in JIA: Delivering tomorrow

Chair: Nicolino Ruperto (Italy)


 

Skalkotas Hall

 

13:00

Chairman’s welcome. Treatment of JIA today: PReSent, but correct?

Nicolino Ruperto (Italy)

13:10

What role can biosimilars play for our patients?

Rieke Alten (Germany)

13:30

Taking JIA into the future: novel therapies and new horizons

Hermine Brunner (USA)

13:50

Interactive audience discussion

All

14:00

Summary and close

Nicolino Ruperto (Italy)

     

13:00 - 14:00

Biomarin & Sanofi Genzyme

When is JIA not JIA? A case-led discussion of its mimics

Chair: Helen Foster (United Kingdom)


 

MC 3 Room
 

13:00

MPS in the rheumatology setting: an introduction

Helen Foster (United Kingdom)

13:10

Red-flag symptoms for MPS: when is JIA not JIA?

Rolando Cimaz (Italy)

13:30

Improving clinical outcomes of MPS patients: treatment and management strategies

Julian Raiman (United Kingdom)

13:50

Questions and summing up

 

 

SATURDAY 16 SEPTEMBER

13:00 - 14:00

Novartis

Novel approaches: Targeting IL-1ß

The molecular signature of autoinflammatory disease

Chair: Jasmin Kümmerle-Deschner (Germany)

Banquet Hall

 

13:00

Living with systemic juvenile idiopathic arthritis and periodic fever syndromes: Perspectives from patients and their caregivers

Nico Wulffraat (The Netherlands)

13:15

New management strategies for Still’s disease

Dirk Föll (Germany) and Eugen Feist (Germany)

13:30

IL-1 Inhibition - Opportunities and challenges in the treatment of periodic fever syndromes

Jasmin Kümmerle-Deschner (Germany)

13:45

Panel Discussion/Q&A

Jasmin Kümmerle-Deschner (Germany)

     

13:00 - 14:00

ENZYVANT

Therapy Refractory JIA? Think Farber Disease

Chair: Seza Ozen (Turkey), Boris Hügle (Germany)

Skalkotas Hall

 

13:00

Greeting and introduction

Seza Ozen (Turkey)

13:05

Sphingolipids in inflammation and Farber disease

Edward H. Schuchman (USA)

13:20

JIA or Farber disease? Clinical spectrum and differential diagnosis

Boris Hügle (Germany)

13:35

Cases from the Pediatric Rheumatology Clinic:

Moderators: Seza Ozen (Turkey), Boris Hügle (Germany)

1. Severe phenotype - Onset in infancy

Bo Magnusson (Sweden)

2. Moderate phenotype - Rapid progression

Balahan Makay (Turkey)

3. Moderate phenotype - Slower progression

Boris Hügle (Germany)

13:55

Summary and conclusion

Boris Hügle (Germany)

 

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy policy and how to manage them on your browser. You can change your cookie settings at any time.    

Cookie PolicyAccept